Smiths Group plc
SMGKF News Today: Stay Updated with the Latest Smiths Group plc News in Real Time
Find SMGKF news now at Meyka AI. Stay informed with the latest Smiths Group plc stocks updates, including price news, market analysis, and expert insights.
TRMD TORM plc Insider Filings: Two Officers Report RSU Holdings May 2026
TORM plc insiders Christensen and Jensen file initial ownership reports for 42,533 RSUs each. Meyka Grade B+.
Vodafone Group Stock Edges Up 0.13% on SIX as Telecom Sector Stabilizes
VOD.SW stock rises 0.13% to CHF1.56 on SIX. Vodafone trades above 50-day average amid sector headwinds and debt challenges.
Kodama Chemical Industry Plummets 28% After Earnings Miss on Weak Auto Demand
4222.T stock crashes 28% to ¥859 after earnings announcement. Auto parts maker faces demand headwinds in Consumer Cyclical sector.
SenseTime Group Inc. (0020.HK) Drops 4.1% as AI Losses Deepen
0020.HK stock falls 4.1% to HK$1.85 as SenseTime faces mounting losses and negative cash flow in AI software sector.
SLNX Stock Surges 400% on Massive Volume Spike in Cannabis Play
SLNX stock jumps 400% year-to-date with 1.3M share volume spike. Solanbridge Group trades at $0.0001 on PNK exchange.
IKEA Franchiser Ingka Group Cuts 850 Jobs as Weak Consumer Spending Pressures Retail Sector
The global retail sector is under pressure again. Ingka Group, the largest operator of the IKEA franchise, has announced the cut of around 850 jobs as weak consumer spending continues to impact demand for home furnishing products. The decision highlights how even strong global brands like IKEA are not immune to economic slowdown. Rising inflation,…
CLNFF: RBC Capital Maintains Outperform Rating, May 2026
RBC Capital maintains Outperform rating on Calian Group (CLNFF), raising price target to C$90 from C$78 on May 15, 2026.
Elior Group SA Stock Slips 2.56% Ahead of May 20 Earnings
ELIOR.PA stock falls 2.56% to €2.888 on EURONEXT ahead of earnings announcement on May 20. Meyka AI rates the catering giant B+.
Addex Therapeutics Ltd Tumbles 12.9% as CNS Drug Pipeline Faces Headwinds
ADXN.SW stock drops 12.9% on May 18. Biotech firm’s CNS drug programs face development challenges amid weak financials.